Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GeneDx Holdings (WGS) Revenue (2020 - 2026)

GeneDx Holdings has reported Revenue over the past 7 years, most recently at $102.3 million for Q1 2026.

  • Quarterly Revenue rose 17.38% to $102.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $442.7 million through Mar 2026, up 34.09% year-over-year, with the annual reading at $427.5 million for FY2025, 39.97% up from the prior year.
  • Revenue was $102.3 million for Q1 2026 at GeneDx Holdings, down from $121.0 million in the prior quarter.
  • Over five years, Revenue peaked at $121.0 million in Q4 2025 and troughed at $36.2 million in Q2 2022.
  • The 5-year median for Revenue is $70.5 million (2024), against an average of $74.9 million.
  • Year-over-year, Revenue soared 92.77% in 2022 and then plummeted 35.96% in 2023.
  • A 5-year view of Revenue shows it stood at $61.4 million in 2022, then decreased by 6.41% to $57.4 million in 2023, then surged by 66.57% to $95.6 million in 2024, then increased by 26.5% to $121.0 million in 2025, then decreased by 15.48% to $102.3 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Revenue are $102.3 million (Q1 2026), $121.0 million (Q4 2025), and $116.7 million (Q3 2025).